CN108410868A - Gcgr表达的反义调节 - Google Patents

Gcgr表达的反义调节 Download PDF

Info

Publication number
CN108410868A
CN108410868A CN201810052777.0A CN201810052777A CN108410868A CN 108410868 A CN108410868 A CN 108410868A CN 201810052777 A CN201810052777 A CN 201810052777A CN 108410868 A CN108410868 A CN 108410868A
Authority
CN
China
Prior art keywords
certain embodiments
nucleosides
compound
seq
modified oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810052777.0A
Other languages
English (en)
Chinese (zh)
Inventor
苏珊·M·弗赖尔
桑杰·巴诺特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of CN108410868A publication Critical patent/CN108410868A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201810052777.0A 2011-09-20 2012-09-20 Gcgr表达的反义调节 Pending CN108410868A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161537007P 2011-09-20 2011-09-20
US61/537,007 2011-09-20
CN201280045717.7A CN103814132B (zh) 2011-09-20 2012-09-20 Gcgr表达的反义调节

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280045717.7A Division CN103814132B (zh) 2011-09-20 2012-09-20 Gcgr表达的反义调节

Publications (1)

Publication Number Publication Date
CN108410868A true CN108410868A (zh) 2018-08-17

Family

ID=47914848

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810052777.0A Pending CN108410868A (zh) 2011-09-20 2012-09-20 Gcgr表达的反义调节
CN201280045717.7A Active CN103814132B (zh) 2011-09-20 2012-09-20 Gcgr表达的反义调节

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280045717.7A Active CN103814132B (zh) 2011-09-20 2012-09-20 Gcgr表达的反义调节

Country Status (16)

Country Link
US (2) US8865674B2 (enExample)
EP (2) EP3401401B1 (enExample)
JP (2) JP6092226B2 (enExample)
KR (1) KR101840512B1 (enExample)
CN (2) CN108410868A (enExample)
AU (2) AU2012312433B2 (enExample)
BR (1) BR112014006587B1 (enExample)
CA (1) CA2849273C (enExample)
DK (1) DK2758533T3 (enExample)
ES (2) ES2673721T3 (enExample)
IL (1) IL231560B (enExample)
IN (1) IN2014CN02736A (enExample)
MX (1) MX353322B (enExample)
NO (1) NO2925947T3 (enExample)
RU (1) RU2598709C2 (enExample)
WO (1) WO2013043817A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013120003A1 (en) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
US9127276B2 (en) 2013-05-01 2015-09-08 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
CN110903337A (zh) 2014-05-01 2020-03-24 Ionis制药公司 用于调节生长激素受体表达的组合物和方法
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
JP6637961B2 (ja) * 2014-08-04 2020-01-29 ミラゲン セラピューティクス， インコーポレイテッド Ｍｙｈ７ｂの阻害剤およびその使用
EP3265098B1 (en) * 2015-03-03 2025-03-26 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
CN107614695B (zh) * 2015-04-02 2022-01-25 瑞美德生物医药科技有限公司 用胰高血糖素受体拮抗性抗体治疗肥胖症和非酒精性脂肪肝病或非酒精性脂肪性肝炎的方法
MX2017012426A (es) * 2015-04-03 2018-01-26 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de tmprss6.
CN108026529A (zh) * 2015-09-30 2018-05-11 Ionis制药公司 组合疗法
MA46089A (fr) 2016-08-30 2019-07-10 Regeneron Pharma Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon
KR20190065341A (ko) 2016-10-06 2019-06-11 아이오니스 파마수티컬즈, 인코포레이티드 올리고머 화합물들의 접합 방법
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
CN108174843B (zh) * 2018-01-24 2018-11-13 广州市进德生物科技有限公司 一种胰高血糖素保护剂及其应用
EP3981431A4 (en) * 2019-03-14 2023-06-28 Rena Therapeutics Inc. Nucleic acid complex for modulating ihh expression
JP2025532127A (ja) 2022-09-23 2025-09-29 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｍｅｃｐ２発現を低減する化合物及び方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266714A1 (en) * 2003-04-28 2004-12-30 Susan Freier Modulation of glucagon receptor expression
CN101321869A (zh) * 2005-09-19 2008-12-10 强生医药研究及开发有限责任公司 胰高血糖素受体表达的调节
CN101553236A (zh) * 2006-05-05 2009-10-07 埃西斯药品公司 调节gccr的表达的化合物和方法

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
WO1992017611A1 (en) 1991-03-28 1992-10-15 The University Of Tennessee Research Corporation Dna silver staining
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
EP0590090A4 (en) 1991-06-18 1995-04-12 Univ Temple SELECTIVE INHIBITATION OF LEUKEMIC CELL PROLIFERATION BY -I (BCR-ABL) ANTISENS OLIGONUCLEOTIDES.
AU655839B2 (en) 1991-06-27 1995-01-12 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5804383A (en) 1992-08-21 1998-09-08 The Regents Of The University Of California Method and assay for detection of the expression of allele-specific mutations by allele-specific in situ reverse transcriptase polymerase chain reaction
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
AU689078B2 (en) 1992-08-28 1998-03-26 Novo Nordisk A/S Glucagon receptors
US6410324B1 (en) 2001-04-27 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of tumor necrosis factor receptor 2 expression
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US5872242A (en) 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
RU95114435A (ru) 1992-12-14 1997-05-20 Ханивелл Инк. (Us) Система с бесщеточным двигателем постоянного тока
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
WO1994025588A2 (en) 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5563036A (en) 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5612455A (en) 1994-07-05 1997-03-18 Tularik, Inc. Nuclear factors and binding assay
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
US7875733B2 (en) 2003-09-18 2011-01-25 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
KR20000065204A (ko) 1997-03-07 2000-11-06 모치다 에이 Cd14에 대한 안티센스 화합물
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6248724B1 (en) 1997-09-25 2001-06-19 University Of Florida Antisense oligonucleotide compositions targeted to angiotensin converting enzyme MRNA and methods of use
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US20030203862A1 (en) 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
ES2221750T3 (es) 1998-07-23 2005-01-01 Gen-Probe Incorporated Metodo para la deteccion y medicion de acidos nucleicos cortados y empalmados.
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US5962673A (en) * 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
US6692959B2 (en) 1998-11-25 2004-02-17 Isis Pharmaceuticals, Inc. Antisense modulation of IL-1 receptor-associated kinase-4 expression
US20030087854A1 (en) 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
KR100820266B1 (ko) 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
JP2002543214A (ja) 1999-05-04 2002-12-17 エクシコン エ／エス Ｌ−リボ−ｌｎａ類縁体
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6492152B1 (en) 1999-06-15 2002-12-10 The Board Of Regents Of The University Of Oklahoma Core 1 β3-galactosyl transferases and methods of use thereof
US6284538B1 (en) 1999-07-21 2001-09-04 Isis Pharmaceuticals, Inc. Antisense inhibition of PTEN expression
WO2001042457A2 (en) 1999-11-29 2001-06-14 Avi Biopharma, Inc. Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s prnas and their uses
US6869762B1 (en) * 1999-12-10 2005-03-22 Whitehead Institute For Biomedical Research Crohn's disease-related polymorphisms
US6602857B1 (en) * 2000-01-18 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) * 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US6770486B1 (en) 2000-02-08 2004-08-03 Isis Pharmaceuticals, Inc. Optimization of ligand affinity for RNA targets using mass spectrometry
EP1268856A2 (de) * 2000-04-07 2003-01-02 Epigenomics AG Detektion von snp's und cytosin-methylierungen
WO2001092524A2 (en) 2000-05-26 2001-12-06 Aeomica, Inc. Myosin-like gene expressed in human heart and muscle
AU2001295010A1 (en) 2000-08-18 2002-03-04 Case Western Reserve University Regulator gene and system useful for the diagnosis and therapy of osteoporosis
WO2002027033A1 (en) * 2000-09-29 2002-04-04 Isis Pharmaceuticals, Inc. Antisense modulation of mekk4 expression
AU2002239538A1 (en) 2000-12-06 2002-06-18 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
WO2003004602A2 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
CA2855445C (en) 2002-06-06 2018-01-09 Monsanto Technology Llc Methods and compositions for production of maize lines with increased transformability
US20040023384A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 12 expression
WO2004044139A2 (en) 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
CN1726008A (zh) * 2002-12-19 2006-01-25 阿尔萨公司 用于从植入装置中传递的稳定的非水单相凝胶及其制剂
US7750142B2 (en) 2003-04-28 2010-07-06 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
BRPI0418104A (pt) 2003-12-23 2007-04-17 Santaris Pharma As compostos oligoméricos para a modulação de bcl-2
US7341835B2 (en) * 2004-01-13 2008-03-11 Affymetrix, Inc. Methods of analysis of alternative splicing in mouse
US7943754B2 (en) * 2004-04-02 2011-05-17 Rosetta-Genomics Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof
WO2005116204A1 (ja) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
EP1799859B1 (en) 2004-09-17 2014-07-02 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
US7399845B2 (en) 2006-01-27 2008-07-15 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7901882B2 (en) 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
JP5825754B2 (ja) * 2006-05-05 2015-12-02 アイシス ファーマシューティカルズ， インコーポレーテッド Ａｐｏｂの発現を調節するための化合物および方法
CN101490074B (zh) 2006-05-11 2013-06-26 Isis制药公司 5’-修饰的双环核酸类似物
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
ATE538127T1 (de) 2007-07-05 2012-01-15 Isis Pharmaceuticals Inc 6-disubstituierte bicyclische nukleinsäureanaloga
KR20100105550A (ko) * 2007-11-09 2010-09-29 아이시스 파마수티컬즈 인코포레이티드 7 인자 발현 조절
EP2222851B1 (en) * 2007-11-20 2017-06-28 Ionis Pharmaceuticals, Inc. Modulation of cd40 expression
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
US9778708B1 (en) 2016-07-18 2017-10-03 Lenovo Enterprise Solutions (Singapore) Pte. Ltd. Dual sided latching retainer for computer modules
US11511972B1 (en) 2019-09-26 2022-11-29 Versatile, Inc. System for tracking lifting events at a construction site

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266714A1 (en) * 2003-04-28 2004-12-30 Susan Freier Modulation of glucagon receptor expression
CN101321869A (zh) * 2005-09-19 2008-12-10 强生医药研究及开发有限责任公司 胰高血糖素受体表达的调节
CN101553236A (zh) * 2006-05-05 2009-10-07 埃西斯药品公司 调节gccr的表达的化合物和方法

Also Published As

Publication number Publication date
ES2673721T3 (es) 2018-06-25
DK2758533T3 (en) 2018-05-28
CN103814132A (zh) 2014-05-21
BR112014006587A8 (pt) 2017-10-03
CA2849273A1 (en) 2013-03-28
AU2017235886B2 (en) 2019-06-27
EP2758533B1 (en) 2018-04-11
EP2758533A4 (en) 2015-08-05
HK1201070A1 (en) 2015-08-21
BR112014006587B1 (pt) 2021-07-27
IN2014CN02736A (enExample) 2015-07-03
KR101840512B1 (ko) 2018-03-20
JP2017123849A (ja) 2017-07-20
US20130116301A1 (en) 2013-05-09
JP2014530004A (ja) 2014-11-17
IL231560A0 (en) 2014-04-30
RU2598709C2 (ru) 2016-09-27
WO2013043817A1 (en) 2013-03-28
CN103814132B (zh) 2018-06-05
US8865674B2 (en) 2014-10-21
KR20140062083A (ko) 2014-05-22
EP3401401A1 (en) 2018-11-14
US20150099792A1 (en) 2015-04-09
ES2796556T3 (es) 2020-11-27
CA2849273C (en) 2020-07-21
AU2017235886A1 (en) 2017-10-19
NZ622398A (en) 2016-07-29
NO2925947T3 (enExample) 2018-03-10
EP2758533A1 (en) 2014-07-30
BR112014006587A2 (pt) 2017-03-28
AU2012312433A1 (en) 2014-04-03
WO2013043817A8 (en) 2014-05-15
EP3401401B1 (en) 2020-04-15
JP6538736B2 (ja) 2019-07-03
AU2012312433B2 (en) 2017-07-06
MX2014003492A (es) 2014-11-10
IL231560B (en) 2018-11-29
MX353322B (es) 2018-01-05
RU2014115215A (ru) 2015-10-27
US9404114B2 (en) 2016-08-02
JP6092226B2 (ja) 2017-03-08

Similar Documents

Publication Publication Date Title
CN108410868A (zh) Gcgr表达的反义调节
CN106146591B (zh) 血管生成素样3表达的调节
AU2016294347B2 (en) Modulators of diacyglycerol acyltransferase 2 (DGAT2)
AU2018211325B2 (en) Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
JP6043347B2 (ja) 線維芽細胞増殖因子受容体４の発現のアンチセンス調節
MX2014005067A (es) Modulacion antisentido de la expresion de gccr.
KR20180105730A (ko) 근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
AU2011237426A1 (en) Modulation of CETP expression
KR101839177B1 (ko) Ｐｔｐｉｂ 발현의 안티센스 조절
KR20210033004A (ko) Rtel1의 발현을 조절하기 위한 올리고뉴클레오티드
CN107405358A (zh) 调节脂肪代谢障碍群体中的载脂蛋白c‑iii(apociii)表达
AU2019201882B2 (en) Modulation of angiopoietin-like 3 expression
HK40036861A (en) Modulation of angiopoietin-like 3 expression
CN108026529A (zh) 组合疗法
HK1255260A1 (en) Combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180817